The Lancet Oncology Q1 Unclaimed

Elsevier Ltd. United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Oncology is a journal indexed in SJR in Oncology with an H index of 382. Journal with a Single blind Peer Review review system, and It has a price of 2395 €. The scope of the journal is focused on Oncology, Cancer,. It has an SJR impact factor of 12,27 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 12,27.

The Lancet Oncology focuses its scope in these topics and keywords: cancer, phase, patients, randomised, care, advanced, openlabel, multicentre, metastatic, doubleblind, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Scopus WOS
Categories: Oncology (Q1)

2395 €

Inmediate OA


Embargoed OA

0 €

Non OA


The Lancet Oncology


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)




No comments ... Be the first to comment!

Aims and Scope

cancer, phase, patients, randomised, care, advanced, openlabel, multicentre, metastatic, doubleblind, cell, risk, placebocontrolled, ipilimumab, breast, myelodysplastic, clinical, combined, ecigarette, myeloma, therapy, abiraterone, prostate, Oncology, Cancer,

Best articles by citations

New screening test for colorectal cancer gets off to a good start

View more

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial

View more

Household surfaces hide secondhand smoke affecting children

View more

An extra defence against skin cancer?

View more

Nature Reviews Cancer online

View more

Australian cancer survival figures greatly improved

View more

FDA licences imatinib mesylate for CML

View more


View more

New nerve-block analgesia for patients with pancreatic cancer

View more

Intracellular fusion antibodies may be suicide for cancer cells

View more

EPA halts cancer-induced weight loss

View more

Allan van Oosterom, President of the EORTC

View more

Amgen's point of view on epoetins

View more

Improving and maintaining human health

View more

Lymphatic entrapment of tumour cells after sentinel lymph-node biopsy for melanoma

View more

Cancer Institute at Chennai: a model for resource-poor countries

View more

Electrolysis being trialled for use in liver cancer

View more

CCI-779: a new targeted anticancer agent

View more

Why do hypoxic cells behave badly?

View more

Correlation of MRI/PET rim enhancement in breast cancer: a delivery related phenomenon with therapy implications?

View more

Low susceptibility genes for breast cancer: the way forward?

View more

Oncology and the media

View more

Oncology and the media

View more

Is red tape stifling the progress of new anticancer drugs?

View more